Editas Medicine, Inc. vs Merck & Company, Inc. — Stock Comparison
Editas Medicine, Inc. (EDIT) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Editas Medicine, Inc. on Q·Score (6.4 vs 5.6 out of 10), led by Quality (4.9 vs 0.2) and Sentiment (7.4 vs 5.4). Editas Medicine, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for EDIT (+128.1%) than for MRK (+6.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ currently unprofitable (-157% margin).
71% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
EDIT vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.4/10 versus Editas Medicine, Inc. (EDIT) at 5.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: EDIT or MRK?
Editas Medicine, Inc. (EDIT) scores higher on Growth (7.8/10 vs 6.4/10). Editas Medicine, Inc. reports revenue growth (232.3% YoY) while Merck & Company, Inc. reports (5.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is EDIT or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (7/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about EDIT vs MRK?
There are 9 analysts covering EDIT with a consensus price target of $6.00, and 26 analysts covering MRK with a consensus target of $152.96. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: EDIT or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (4.9/10 vs 0.2/10). Net profit margin: EDIT at -157.3%, MRK at 4.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: EDIT or MRK?
Editas Medicine, Inc. (EDIT) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: EDIT at 2.09, MRK at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of EDIT and MRK?
Editas Medicine, Inc. (EDIT) has a market capitalisation of $404M, while Merck & Company, Inc. (MRK) has a market cap of $354.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do EDIT or MRK pay dividends?
EDIT does not currently pay a dividend, while MRK pays a dividend yield of 2.35%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →